Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2504
http://purl.obolibrary.org/obo/NCIT_C2504
|
|---|---|
| Preferred Name | Vadimezan |
| Definitions |
A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages. |
|---|---|
| prefLabel | Vadimezan
|
| label | Vadimezan
|
| PDQ_Closed_Trial_Search_ID | 43320
|
| code | C2504
|
| prefixIRI | NCIT:C2504
|
| in_subset |
See more
See less
|
| Display_Name | Vadimezan
|
| Preferred_Name | Vadimezan
|
| FDA_UNII_Code | 0829J8133H
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C17H14O4
|
| Maps_To | Vadimezan
|
| CAS_Registry | 117570-53-3
|
| NSC Number | 640488
|
| NCI_Drug_Dictionary_ID | 43320
|
| Legacy Concept Name | Dimethylxanthenone_Acetic_Acid
|
| type | |
| ALT_DEFINITION | An anticancer drug that is a type of angiogenesis inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43320
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C2930490
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |